Announcing ROS1-fusion Research Study: Now Enrolling Patients Like You (January 2019 – Press Release)

We are happy to share an incredible opportunity from our sister organization! A new research study is currently open to enrollment that would give you the unique opportunity to be at the forefront of lung cancer research. Please reviews the details and feel free to share this with other patients that have the ROS1-fusion.

Thank you for your participation in the Lung Cancer Registry! This message is coming to you because you indicated you have the ROS1 mutation.

We are happy to share an incredible opportunity from our sister organization! A new research study is currently open to enrollment that would give you the unique opportunity to be at the forefront of lung cancer research. Please reviews the details and feel free to share this with other patients that have the ROS1-fusion.

LCMI-006 PDX Study Open to Enrollment

The Addario Lung Cancer Medical Institute (ALCMI), Christine Lovly, MD, PhD of Vanderbilt-Ingram Cancer Center, ROS1ders (a patient driven research group), and Champions Oncology are working together with the goal of learning more about the rare genetic mutation known as ROS1-fusion. The goal of this study is to understand what drives tumor development, response to therapies, and acquired resistance. With this knowledge, doctors and researchers will be able to develop new and more effective therapies to fight against this rare and under-studied mutation.

ROS1 rearrangements occur in 1 to 3 % percent of all cancers including lung, gastric and ovarian cancers, as well as melanoma, cholangiocarcinoma, glioblastoma and other cancers. ROS1 is an enzyme coded by the ROS1 gene. A gene fusion occurs when a gene abnormally breaks off and fuses with another gene to form a hybrid gene that can lead to cancer initiation and drive its growth.

A patient-derived xenograft, otherwise known as PDX model, is created by implanting a fresh piece of tumor tissue from a procedure into an immunodeficient mouse. This allows the mouse to act as a “host” and grow the tumor in a way that is similar to the original human tumor. This studywill result in a model that will help researchers understand the response and resistance of ROS1 positive cancer.

To participate in the study or for more information, call Nurse Alicia at 866-988-ROS1 (7671) or go to www.alcmi.net/ROS1PDXstudy.

Ready to collaborate with some of the top institutions in the United States to drive lung cancer research? Share this opportunity with others and participate today! Thank you for your time and ongoing support of the Lung Cancer Registry. Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
Bonnie J. Addario Lung Cancer Foundation
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lungcancerregistry.org